{"id":686053,"date":"2024-01-29T15:26:01","date_gmt":"2024-01-29T15:26:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=686053"},"modified":"2024-01-29T15:26:01","modified_gmt":"2024-01-29T15:26:01","slug":"amplyx-pharmaceuticalss-fosmanogepix-market-size-expected-to-increase-many-folds-by-2032-report-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/amplyx-pharmaceuticalss-fosmanogepix-market-size-expected-to-increase-many-folds-by-2032-report-delveinsight_686053.html","title":{"rendered":"Amplyx Pharmaceuticals\u2019s FOSMANOGEPIX market size expected to increase many folds by 2032, report DelveInsight"},"content":{"rendered":"
\n
\"Amplyx<\/a><\/div>\n
\n
FOSMANOGEPIX Drug Market Forecast and Analysis<\/div>\n<\/div>\n<\/div>\n
\u201cFOSMANOGEPIX- Market Size, Forecast, and Emerging Insight \u2013 2030\u201d the report provides comprehensive insights about an investigational product for Candidemia in 7 Major Markets. A detailed picture of the FOSMANOGEPIX in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020\u20132030 is provided in this report along with a detailed description of the product.<\/div>\n

DelveInsight has recently published a report on “FOSMANOGEPIX Market Forecast Report<\/a>” providing an in-depth analysis of the FOSMANOGEPIX market analysis and forecasts up to 2032 in the seven major markets (7MM) (i.e. the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The comprehensive report provides an analysis of FOSMANOGEPIX market potential and market share analysis in the fungal infections therapeutics space across the 7MM from 2019 to 2032. <\/p>\n

The report also helps you to understand the FOSMANOGEPIX clinical and commercial developments along with parameters like the drug’s Mechanism of Action (MOA), Route of Administration (ROA), dosage, and special designations.<\/p>\n

Interested in finding out the projected market size of FOSMANOGEPIX by 2032? Visit: FOSMANOGEPIX Market Forecast<\/a><\/strong><\/p>\n

FOSMANOGEPIX Drug Summary<\/strong><\/p>\n

Fosmanogepix is a clinical-stage broad-spectrum antifungal. It has a novel mechanism of action and its active moiety has shown activity against common species of Candida and Aspergillus, including multi-drug-resistant strains, such as Candida auris and Candida glabrata, as well as rare difficult-to-treat molds including Fusarium spp., Scedosporium spp., and some fungi from the Mucorales order. Fosmanogepix’ intravenous and oral formulations have been evaluated in clinical phase 2 studies for the treatment of patients with Candidemia, including Candida auris, and invasive mold infections.<\/p>\n

Fosmanogepix has received Fast Track and Orphan Drug designations from the US Food and Drug Administration for seven separate indications, and is designated as a Qualified Infectious Disease Product (QIDP) for the treatment of four indications.<\/p>\n

Stay ahead of the competition by leveraging key insights and evolving trends in the FOSMANOGEPIX FOSMANOGEPIX Market @ FOSMANOGEPIX Market Outlook and Key Assessment<\/a><\/strong><\/p>\n

Key Highlights of the FOSMANOGEPIX Market Report<\/strong><\/p>\n